Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc (NCNA) is a clinical-stage biopharmaceutical company pioneering ProTide technology to develop enhanced cancer therapeutics. This page provides investors and researchers with essential updates on clinical trials, regulatory developments, and scientific advancements related to NuCana's innovative approach to overcoming chemotherapy resistance.
Key resources include: Press releases detailing clinical progress, analyses of pipeline candidates for solid tumors, and updates on phosphoramidate chemistry applications. Users will find verified information on drug safety profiles, trial designs, and strategic collaborations.
Regular updates cover:
- Phase I-III clinical trial results
- Regulatory submissions and FDA communications
- Scientific conference presentations
- Intellectual property developments
Bookmark this page for structured access to NuCana's latest advancements in reengineering conventional chemotherapy agents through proprietary nucleotide analog technology. Check back for objective reporting on innovations designed to improve intracellular drug activation in cancer cells.
NuCana plc (NASDAQ: NCNA) announced that the European Patent Office's Technical Board of Appeal ruled that its European Patent 2955190 is not valid. The decision reverses earlier validations from 2021 and a judgment in the UK on March 21, 2023, which also deemed the patent invalid. Despite this setback, NuCana emphasized that it will not impair its anti-cancer ProTide therapies, as they are protected by other patents. CEO Hugh S. Griffith reassured stakeholders that the company remains financially stable, with all clinical programs on track and multiple data announcements expected in 2023.
NuCana plc (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will participate in two coming investor conferences. The first is Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 AM ET, and the second is Oppenheimer's 33rd Annual Healthcare Conference on March 14, 2023, at 12:40 PM ET. Both presentations will be available for live webcast and replay in the Investors section of the company's website.
NuCana is focused on enhancing cancer treatments via its ProTide technology, with key products NUC-3373 and NUC-7738 undergoing various clinical trials. The company aims to improve patient outcomes with these advancements.
NuCana plc (NASDAQ: NCNA) announced it has regained compliance with Nasdaq's minimum bid price requirement, having maintained a closing bid price of $1.00 or more for 10 consecutive business days from January 5 to January 19, 2023. Previously, the company was notified on January 6, 2023, that its American Depositary Shares (ADSs) had fallen below the $1.00 threshold for over 30 days. The Notification Letter confirms that the matter is now resolved. NuCana focuses on enhancing cancer treatment outcomes through its ProTide technology, with ongoing clinical studies for its drug candidates NUC-3373 and NUC-7738.
NuCana plc (NASDAQ: NCNA) received a Notification Letter from Nasdaq on January 3, 2023, indicating that the company's American Depositary Shares (ADSs) have fallen below the minimum bid price requirement of $1.00 per share for 30 consecutive business days.
The notification does not affect the current listing of ADSs, which will continue to trade on Nasdaq. NuCana has a 180-day grace period, until July 3, 2023, to regain compliance by maintaining a share price of $1.00 or higher for 10 consecutive days. Failing to do so may lead to a transfer to Nasdaq Capital Market.
NuCana plc (NASDAQ: NCNA) will participate in the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco, holding one-on-one meetings. The company focuses on enhancing cancer treatment outcomes via its proprietary ProTide technology, converting standard chemotherapy agents into safer medicines. NuCana's pipeline includes NUC-3373 for metastatic colorectal cancer and NUC-7738 for advanced solid tumors, both undergoing various phases of clinical trials.
NuCana plc (NASDAQ: NCNA) reported Q3 financial results for 2022, showing a reduced net loss of £4.5 million, down from £8.0 million year-over-year. Cash reserves increased to £50.8 million, providing a runway through 2025. The company advances its ProTide therapeutics, with two Phase 2 studies initiated for NUC-3373 in colorectal cancer and solid tumors. Positive data were presented at major oncology meetings, enhancing confidence in NUC-3373 and NUC-7738's effectiveness. Key milestones are anticipated in Q4 2022 and the first half of 2023.
NuCana plc (NASDAQ: NCNA) will present at the Jefferies London Healthcare Conference on November 16, 2022, at 2:40 PM GMT. CEO Hugh Griffith and CFO Don Munoz will lead discussions and one-on-one meetings at the event held in London, UK. The presentation will be available for live webcast and later replay on the company’s website under ‘Events & Presentations’. NuCana focuses on enhancing cancer treatment through its ProTide technology, with a pipeline including NUC-3373 and NUC-7738.
NuCana plc (NASDAQ: NCNA) announced promising non-clinical results for NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting. Data suggest NUC-3373, a potent thymidylate synthase (TS) inhibitor, induces significant DNA damage in various non-small cell lung cancer (NSCLC) cell lines and increases immunogenic activity. The company has initiated the NuTide:303 study, evaluating NUC-3373 in combination with pembrolizumab or docetaxel for patients with advanced solid tumors. Results highlight NUC-3373's potential as a significant treatment option for NSCLC, reinforcing the company's strategic focus on enhancing chemotherapy efficacy.
NuCana plc (NASDAQ: NCNA) presented promising results for NUC-7738 at the ESMO Annual Meeting, indicating significant anti-tumor activity in advanced solid tumors, particularly melanoma. The Phase 1 data of the NuTide:701 study showed that many patients remained on treatment for extended periods, with low rates of treatment-related adverse events. NUC-7738, which aims to enhance the anti-cancer effects of 3'-deoxyadenosine, is set to proceed to Phase 2 trials, including a combination with pembrolizumab. The favorable safety profile and potential efficacy mark a significant step forward for NuCana's cancer treatment pipeline.
NuCana plc (NASDAQ: NCNA) announced positive results from its NuTide:302 study on NUC-3373, demonstrating good anti-tumor activity and safety in heavily pre-treated colorectal cancer patients. Data presented at the ESMO Annual Meeting showed that both NUFIRI and NUFOX regimens yielded promising progression-free survival rates, with 80% disease control for NUFOX. A new randomized study, NuTide:323, has been initiated, comparing NUFIRI with FOLFIRI. NUC-3373 aims to improve on 5-FU's limitations, potentially transforming treatment for colorectal cancer.
